← Back to Search

Radiotherapy + Pembrolizumab for Adrenocortical Cancer

Phase 2

Recruiting

Led By Nitya Raj, MD

Research Sponsored by Memorial Sloan Kettering Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Have histologically- or cytologically- confirmed metastatic ACC with symptomatic liver metastases

Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 1 year

Awards & highlights

Study Summary

This trial tests a new cancer treatment to see if it's safe and causes few or mild side effects.

Who is the study for?

Adults with advanced Adrenocortical Carcinoma (ACC) and liver metastases, ECOG performance status of 0, measurable disease, adequate organ function. Must not have had recent treatments or other cancers, no active infections or immunodeficiencies, and agree to contraception.Check my eligibility

What is being tested?

The trial is testing the safety and side effects of Pembrolizumab following ablative Radiotherapy in patients with ACC. The goal is to see if this combination treatment causes few or mild side effects.See study design

What are the potential side effects?

Potential side effects may include immune system reactions affecting organs, fatigue, skin reactions, digestive issues and changes in blood tests. Specific risks will be monitored closely throughout the study.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My cancer has spread to my liver and is causing symptoms.

Select...

I am fully active and can carry on all pre-disease activities without restriction.

Select...

My cancer has spread outside of the liver.

Select...

I am 18 years old or older.

Select...

I am using two birth control methods or am not able to have children, and will continue for 120 days after the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Number of participants evaluated for AEs

Trial Design

1Treatment groups

Experimental Treatment

Group I: Participants with Adrenocortical CarcinomaExperimental Treatment2 Interventions

Participants with histologically proven metastatic Adrenocortical Carcinoma/ACC with both intra-hepatic and extra-hepatic sites of disease.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Pembrolizumab

2017

Completed Phase 2

~2010

0 / 5Eligibility criteria met

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor

1,936 Previous Clinical Trials

588,886 Total Patients Enrolled

Nitya Raj, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center

1 Previous Clinical Trials

53 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this research accepting new volunteers at present?

"The clinical research is presently recruiting participants; the listing was initially posted on September 27th in 2023 and was most recently modified on that same date."

Answered by AI

Does the FDA have any regulations in place for treating Participants with Adrenocortical Carcinoma?

"Our team at Power has graded the safety of Adrenocortical Carcinoma participants a 2 due to being in Phase 2 trials, where there is some data available for evaluating safety but no evidence yet quantifying efficacy."

Answered by AI

What is the capacity of the participants in this experiment?

"Correct. The clinical trial data housed on clinicaltrials.gov affirms that recruitment is ongoing for the study, which has been posted since September 27th 2023 and last modified on the same date. A total of 12 patients are being sought from 7 different sites."

Answered by AI

How many distinct venues is the trial being implemented in?

"7 medical centres are presently recruiting for this trial, which include locations in Middletown, Montvale and Commack. To minimize travel demands when participating, it is recommended that individuals select the location nearest to them."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma

2023. "Study of Radiotherapy and Pembrolizumab in People With Adrenocortical Carcinoma". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT06066333.